Diagnos Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) has provided an update on the regulatory pathway for its CARA artificial intelligence platform, which is designed for early detection of eye-related health issues. The update follows the company's previously announced acceleration plan and confirms progress across three targeted jurisdictions.
The company has made a formal submission to the Saudi Food and Drug Authority (SFDA) for marketing approval of the CARA platform. Additionally, Diagnos is engaged with Health Canada, with a formal application expected within this quarter. In the United States, the company has clarified the 510(k) requirements with the U.S. Food & Drug Administration (FDA), positioning CARA for potential commercialization in key global markets.
This regulatory progress is significant as it moves Diagnos closer to bringing its AI-driven diagnostic tool to market. CARA aims to assist healthcare clinicians by providing more information to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes. The platform focuses on early detection of critical eye-related health problems, which could have a substantial impact on public health by enabling earlier intervention.
For more details, the full press release can be accessed at https://ibn.fm/uUewJ.
Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems using Artificial Intelligence. Additional information about the company is available at www.diagnos.com and www.sedarplus.com.
Investors seeking the latest news and updates relating to DGNOF can visit the company's newsroom at https://ibn.fm/DGNOF.
This announcement underscores Diagnos's commitment to advancing its AI technology for eye health and navigating the regulatory landscape to bring innovative solutions to patients and clinicians worldwide.
